Skip to main content
Log in

The RACE Study in Perspective of Randomized Studies on Management of Persistent Atrial Fibrillation

  • Published:
Cardiac Electrophysiology Review

Abstract

Atrial fibrillation is the most common sustained cardiac arrhythmia. Treatment strategies are focused on reducing symptoms and minimizing the risks of atrial fibrillation like stroke and heart failure. First choice therapy is the rhythm control strategy, with restoration of sinus rhythm. Drawback of this approach is the low success rate for maintenance of sinus rhythm. Outcome will improve with the use of antiarrhythmic drugs after electrical cardioversion, unfortunately exposing the patient to the risks of life threatening pro-arrhythmia. The second alternative, a rate control strategy, is easy to achieve but it is unknown whether this treatment strategy results in higher morbidity and mortality rates. RACE (RAte Control versus Electrical cardioversion for persistent atrial fibrillation) was a prospective randomized trial comparing both strategies. The primary end point was a composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, pacemaker implants and severe adverse effects of drugs. After a mean follow-up of 2.3 years, the primary end point occurred in 44 of the 256 rate control patients (17.2%) and 60 of the 266 rhythm control patients (22.6%). Other trials as the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management), PIAF (Pharmacological Intervention in Atrial Fibrillation) and STAF (Strategies of Treatment of Atrial Fibrillation) also found that rate control was not inferior to rhythm control in terms of morbidity, mortality and quality of life. These four randomized trials demonstrated that a rate control strategy is an acceptable alternative to rhythm control in patients with recurrent atrial fibrillation. For those with severely symptomatic atrial fibrillation, continued rhythm control is unavoidable. For these patients, safer and more effective methods of maintaining sinus rhythm are needed to reduce morbidity related to palpitations and atrial fibrillation-induced heart failure.

Furthermore, the randomized studies showed that rhythm control therapy does not prevent stroke. It was observed from RACE that 21 of the 35 thromboembolic complications occurred under rhythm control, the majority while receiving inadequate anticoagulation therapy. Also in AFFIRM, with patients with one or more stroke risk factors, more strokes were present under rhythm control. Therefore, one of the main lesson learned from the randomized studies is that anticoagulation must be continued if stroke risk factors are present even if patients maintain sinus rhythm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469–473.

    Google Scholar 

  2. Van Gelder IC, Crijns HJGM, Tieleman RG, Brugemann J, de Kam PJ, Gosselink AT, Verheugt FW, Lie KI. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585–2592.

    Google Scholar 

  3. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JGP, Crijns HJGM. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834–1840.

    Google Scholar 

  4. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.

    Google Scholar 

  5. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789–1794.

    Google Scholar 

  6. Carlsson JJ, Miketic S, Windeler JJ, Cuneo A, Haun S, Micus S, Walter S, Tebbe U. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation. The Strategies of Treatment of Atrial Fibrillation (STAF) study. J AmColl Cardiol 2003;41:1690–1696.

    Google Scholar 

  7. Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol 1998;82:18N–28N.

    Google Scholar 

  8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983–988.

    Google Scholar 

  9. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003;138:831–838.

    Google Scholar 

  10. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316–1320.

  11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870.

    Google Scholar 

  12. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study. The College of French Cardiologists. Circulation 1999;99:3028–3035.

    Google Scholar 

  13. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. JAmColl Cardiol 1993;22(Suppl A):6A–13A.

    Google Scholar 

  14. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: Epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91(6A):2–8.

    Google Scholar 

  15. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002;144:597–607.

  16. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J AmColl Cardiol 2000;35:183–187.

    Google Scholar 

  17. Falk RH. Management of atrial fibrillation-Radical reform or modest modification? N Engl J Med 2002;347:1883–1884.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagens, V.E., Van Gelder, I.C. & Crijns, H.J. The RACE Study in Perspective of Randomized Studies on Management of Persistent Atrial Fibrillation. Card Electrophysiol Rev 7, 118–121 (2003). https://doi.org/10.1023/A:1027439430017

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1027439430017

Navigation